What Is Brugada Syndrome? Causes, Symptoms, and Treatment

Brugada syndrome is a genetic heart condition that disrupts the electrical system of an otherwise structurally normal heart, raising the risk of dangerous heart rhythms and sudden cardiac death, particularly in young adults. It was one of the last major cardiac conditions identified in the twentieth century, and despite decades of research, it remains tricky to diagnose and manage because its hallmark abnormalities on an electrocardiogram can appear and disappear unpredictably. The condition disproportionately affects people of Southeast Asian descent and men far more than women, and its severity ranges widely, from people who never experience a single symptom to those whose first sign is a cardiac arrest.

The Genetic Roots

Brugada syndrome is caused by defects in the ion channels that control the heart’s electrical signals. The best-understood culprit is the SCN5A gene on chromosome 3, which encodes part of the sodium channel responsible for initiating each heartbeat’s electrical impulse. Mutations in SCN5A reduce the flow of sodium into heart cells, throwing off the delicate electrical balance that keeps the heart beating in a coordinated rhythm.¹ Research has shown that patients carrying an SCN5A mutation tend to have enlarged heart chambers and reduced pumping ability compared with those who do not carry the mutation, suggesting the sodium channel plays a role in maintaining the heart’s structural integrity as well.²

However, SCN5A mutations account for only a minority of cases. Many patients diagnosed with Brugada syndrome have no identifiable SCN5A variant, and researchers now recognize the condition has features of a polygenic disease, meaning multiple genes and common genetic variations may collectively influence a person’s risk.³ The condition follows an autosomal dominant inheritance pattern, so a child of someone with Brugada syndrome has roughly a one-in-two chance of inheriting the relevant genetic change. But inheriting the gene does not guarantee symptoms; many carriers live their entire lives without incident.

How Common It Is and Who It Affects

Estimates of Brugada syndrome’s prevalence vary widely by region. A systematic review and meta-analysis found that the condition is most common in Southeast Asia, where roughly 1.8 per 1,000 people show the characteristic ECG pattern. The syndrome is about nine times more common in Asian populations than in Caucasians and 36 times more common than in Hispanic populations, with the lowest prevalence reported in North Africa.⁴ European estimates generally fall in the range of 1 to 5 per 10,000.⁵

Men are diagnosed far more often than women. In the large meta-analysis of patients who received implantable defibrillators, only about 18% were women.⁶ Testosterone appears to play a role in this sex difference, which is one reason the condition typically manifests in adulthood rather than childhood, though pediatric cases do occur.

Symptoms and Warning Signs

Many people with Brugada syndrome have no symptoms at all and are only identified through family screening or an incidental ECG finding. When symptoms do occur, they tend to strike during rest or sleep rather than during exercise. Patients can experience fainting spells, seizures, and gasping or labored breathing during the night, all driven by episodes of dangerously fast heart rhythms originating in the ventricles.⁷ In the worst cases, the first and only symptom is sudden cardiac arrest.

The nocturnal pattern is distinctive. In Southeast Asia, Brugada syndrome has long been recognized as a cause of sudden unexplained death during sleep in young men, a phenomenon known locally by various names. The link between sleep, vagal tone (the body’s “rest and digest” nervous system activity), and arrhythmia risk is well established in this condition and distinguishes it from many other cardiac disorders where exercise is the primary trigger.

What Triggers Arrhythmias

Certain conditions can unmask or worsen the ECG abnormalities and push a vulnerable heart into a dangerous rhythm. Fever is one of the most important triggers. A study published in the Annals of Internal Medicine confirmed that fever increases the risk of cardiac arrest in Brugada syndrome patients.⁸ In children with the condition, fever was identified as the most important factor precipitating arrhythmic events.⁹ This means that aggressive fever management with antipyretics is a cornerstone of day-to-day care for anyone diagnosed with the syndrome.

Beyond fever, a range of other factors can temporarily bring out the telltale ECG changes, including electrolyte imbalances (particularly abnormal potassium levels), certain medications, and even heavy meals that increase vagal tone.¹⁰ Maintaining an up-to-date awareness of which drugs are safe and which should be avoided is critical. Publicly available online databases (such as brugadadrugs.org) catalog hundreds of medications by their risk level, covering everything from common antibiotics to over-the-counter cold remedies.

How Brugada Syndrome Is Diagnosed

Diagnosis hinges on the electrocardiogram. Three ECG patterns have been described in Brugada syndrome, but only one is considered diagnostic: the type 1 “coved-type” pattern, which shows a distinctive dome-shaped ST-segment elevation in the right-sided chest leads (V1 through V3).¹¹ The type 2 “saddle-back” pattern raises suspicion but is not enough on its own to confirm the diagnosis.

Because the ECG pattern can come and go, many patients have a normal-looking ECG at the time of their doctor’s visit. When suspicion is high but the resting ECG is inconclusive, a drug challenge test can be performed. A sodium channel blocker such as ajmaline, flecainide, or procainamide is administered intravenously under close monitoring. If the drug provokes the type 1 ECG pattern, the diagnosis is confirmed.¹²¹³

One diagnostic wrinkle worth knowing about is the Brugada phenocopy, a condition in which some other medical problem (such as a severe electrolyte disturbance or myocarditis) produces an ECG that looks identical to Brugada syndrome. Research has shown that even expert cardiologists cannot visually tell the two apart, which is why systematic clinical criteria beyond the ECG itself are needed to avoid misdiagnosis.¹⁴ The distinction matters because a phenocopy resolves when the underlying trigger is treated, whereas true Brugada syndrome is a lifelong condition.

Sorting Out Who Is at Highest Risk

Not everyone with a Brugada ECG pattern faces the same level of danger. Risk stratification is an active area of debate, but two factors have consistently been shown to predict dangerous arrhythmic events: a history of unexplained fainting and a spontaneous (not drug-provoked) type 1 ECG pattern.¹⁵ A large 2024 study in the Journal of the American College of Cardiology confirmed that a history of unexplained syncope and a spontaneous type 1 pattern at diagnosis remained strong independent predictors of life-threatening arrhythmic events during follow-up.¹⁶

People who have already survived a cardiac arrest are at the highest risk of a repeat event. At the other end of the spectrum, asymptomatic patients whose type 1 pattern only appears during a drug challenge face a much lower annual event rate. The challenge lies in the large middle ground: patients with a spontaneous type 1 ECG but no symptoms, or those with vague symptoms that are hard to attribute definitively to arrhythmia. For these groups, treatment decisions are genuinely difficult and often individualized.

Treatment Options

There is no cure for Brugada syndrome, but several strategies can reduce the risk of sudden death. Management ranges from conservative lifestyle measures in low-risk patients to device implantation and ablation procedures in those at higher risk.

Lifestyle and Conservative Measures

For asymptomatic patients, the first line of management involves avoiding known triggers. That means promptly treating fevers, steering clear of drugs that can provoke arrhythmias, and limiting excessive alcohol intake.¹⁷ Patients are typically advised to carry a list of medications to avoid and to inform all healthcare providers about their diagnosis before any procedure or prescription.

Implantable Cardioverter-Defibrillators

The implantable cardioverter-defibrillator (ICD) is the most established treatment for patients deemed at significant risk. The device continuously monitors heart rhythm and delivers an electric shock if it detects a life-threatening arrhythmia. A meta-analysis pooling data from over 1,500 Brugada syndrome patients who received ICDs found an appropriate shock rate of about 3.1 per 100 person-years and very low cardiac mortality (0.03 per 100 person-years), suggesting the device effectively prevents sudden death in high-risk individuals.⁶

ICDs are not without drawbacks, however. In a long-term follow-up study spanning an average of about nine years, roughly one in five patients experienced an ICD-related complication, and about 9% received inappropriate shocks, meaning the device fired when it should not have.¹⁸ Because patients with Brugada syndrome are often diagnosed in their thirties or forties, they face decades of living with the device, including lead replacements, battery changes, and the psychological burden of potential shocks.

Medications

No drug has been proven in large randomized trials to prevent sudden death in Brugada syndrome, but quinidine and isoproterenol have shown benefit in specific situations. During an electrical storm, when a patient experiences repeated episodes of ventricular fibrillation, intravenous isoproterenol can suppress the arrhythmias acutely, and oral quinidine can help prevent recurrences over the longer term.¹⁹²⁰ Quinidine is sometimes used in patients who decline an ICD or as an add-on in those who continue to have arrhythmias despite having one. Its availability has been limited in some countries, which has complicated long-term management.

Catheter Ablation

A newer and increasingly studied approach involves ablating the abnormal electrical substrate in the heart. The arrhythmia-generating tissue in Brugada syndrome sits primarily on the outer surface (epicardium) of the right ventricular outflow tract. In a large multicenter registry (BRAVO), 96% of patients remained free of ventricular fibrillation recurrence after an average follow-up of four years following one or two ablation procedures.²¹ Hybrid thoracoscopic approaches, which allow direct visualization of the epicardial surface through small incisions, have also been explored with promising early results.²²

Ablation is still considered investigational in many centers and is not yet a standard replacement for an ICD. However, case reports exist of patients who refused an ICD and underwent ablation as the sole treatment, with favorable outcomes over the medium term.²³ As data from longer follow-up periods accumulate, ablation may shift from a last-resort option to a front-line therapy for selected patients.

Brugada Syndrome in Children

Pediatric cases are rare but carry distinct challenges. Most children identified with Brugada syndrome are asymptomatic and come to attention through family screening after a parent or sibling is diagnosed.²⁴ When children do develop symptoms, the initial presentation can look different from adults. Sinus node dysfunction and abnormal atrial rhythms can be early signs, and fever is the dominant trigger for arrhythmic events. In the largest reported pediatric series, five of ten symptomatic children had syncope precipitated by fever.⁹

Deciding whether to implant an ICD in a child is particularly difficult. The device must be maintained through decades of growth and physical activity, lead complications are more common in younger patients, and the psychological impact of living with an ICD during formative years is substantial. Dutch expert guidance recommends performing an ECG during fever in children suspected of carrying the syndrome and restricting genetic testing to the SCN5A gene to keep the process focused.²⁵ Because most pediatric cardiologists will encounter the condition only rarely, management typically involves close collaboration with specialized arrhythmia centers.

Anesthesia and Surgery Risks

If you have Brugada syndrome and need surgery, the anesthetic plan requires careful attention. Propofol, one of the most commonly used anesthetic drugs, has been repeatedly linked to arrhythmia-triggering effects in Brugada syndrome patients. Certain local anesthetics, particularly long-acting ones like bupivacaine and ropivacaine, also raise concern because they block sodium channels in a way that can worsen the underlying electrical defect.²⁶

Despite these warnings, a large 18-year study of anesthesia management in Brugada syndrome patients found that drugs classified as “not recommended” were used in about two-thirds of procedures, yet the rate of serious arrhythmic events was only around 1%.²⁷ A separate retrospective study of regional anesthesia using local anesthetics in Brugada syndrome patients did not find an increased rate of arrhythmias or adverse events, though the authors cautioned that the data were too limited to confirm safety definitively.²⁸ The takeaway is not that these drugs are safe but that with continuous ECG monitoring and an external defibrillator at hand, the risk can be managed. Informing the anesthesiologist well before any procedure is essential.

The Psychological Side of the Diagnosis

Living with a condition that can cause sudden death without warning carries a heavy psychological toll that does not always get the clinical attention it deserves. In a study of 223 Brugada syndrome patients with no prior psychiatric history, about 16% developed new-onset depression or anxiety after receiving their diagnosis. Those who had already experienced symptoms like fainting or cardiac arrest were at higher risk of mental health complications.²⁹

The burden is especially pronounced in patients with an ICD. Research has found that roughly 20 to 30% of ICD recipients experience clinically significant anxiety or depression. Among Brugada syndrome patients specifically, about three-quarters of those who had received at least one shock from their device reported that it worsened their quality of life, compared with just over half of those who had never been shocked. Younger patients tended to report a greater negative impact from the ICD on daily life.³⁰ These findings underline why routine psychological screening should be part of long-term follow-up, particularly for younger patients and those who have experienced device shocks.

Artificial Intelligence and Future Diagnostics

Because the ECG pattern in Brugada syndrome can be subtle or intermittent, researchers have begun exploring whether artificial intelligence might help catch cases that human eyes miss. AI algorithms trained on large ECG databases can detect patterns associated with Brugada syndrome, including some that fall below the threshold experienced cardiologists would flag.³¹ The same AI tools are being developed to help interpret genetic variants of uncertain significance, which are common when patients undergo genetic testing and leave both families and clinicians unsure how to act. These tools are still in early stages, but they may eventually allow broader screening in populations that currently go undiagnosed, particularly in regions with limited access to specialist electrophysiologists.